Department of
Molecular Virology
Gdańsk, Poland
Department of Molecular Virology is divided into two units:

- Laboratory of Virus Molecular Biology
- Laboratory of Recombinant Vaccines

Genesis and development of the Department:

The Department of Molecular Virology was founded on June 27th, 1996 and on November 27, 2003 received final educational and
administrative status. Professor Bogusław Szewczyk is the head of the
Department since the foundation of this unit. On June 25, 2005 two
independent scientific laboratories within the Department received
official names: Laboratory of Recombinant Vaccines and Laboratory of
Viral Molecular Biology.

Scientific collaboration:

The Laboratory of Virus Molecular Biology closely cooperates with
many European and American scientific groups. The research is
supported by EU 5th and 6th Framework Programs and by Polish
Ministry of Science.

Since 1998 we participate in international projects founded by EU and
individual bi-lateral collaborations. Some of our close collaborators are:
prof.E. Wiertz, Leiden University (LUMC), The Netherlands; prof. A.
Patel, Institute of Virology, MRC  Glasgow , UK; prof. A. Nicosia ,
Okairos company, Italy; prof. H. Favoreel, Gent University, Belgium; Dr J.K. Ball, University of Nottingham, UK.

The studies of viral proteins responsible for evasion of immunological
response of the host are carried out in the
cooperation with Leiden University in the Netherlands and Ghent
University in Belgium.

The Laboratory of Recombinant Vaccines closely cooperates with
many European, South American and Polish scientific groups. The
studies on the application of baculovirus as a biopesticide are done in
cooperation with Biological Control Unit EMBRAPA and the University
of Goiania in Brazil.

The studies of the effect of glycosylation inhibitors on flavivirus
replication is a joint project of the Laboratory of Recombinant
Vaccines, Pharmaceutical Institute in Warsaw, Silesian Technical
University in Gliwice and MRC in Glasgow.

The research on the construction of a cheap recombinant vaccine
against bird flu virus is financed mainly by the programme Innovative
Technologies (Innowacyjna Gospodarka). The research consortium
consists of the Institute of Biotechnology and Antibiotics in Warsaw,
Institute of Biochemistry and Biophysics in Warsaw, National Veterinary Institute in Puławy and our Laboratory.